Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1231230 | 0.82 | GAA (0.47) | ATMLMNAL3MBTL1GAACYP1A2 | |
| SCHEMBL7566570 | 0.81 | ATM (0.40) | ATMLMNAL3MBTL1CYP1A2HIF1A | |
| SCHEMBL21102900 | 0.81 | CYP1A2 (0.35) | ATMLMNAL3MBTL1GAACYP1A2 | |
| Hydrochloric Acid SCHEMBL9993297 | 0.81 | GAA (0.45) | ATMLMNAL3MBTL1GAACYP1A2 | |
| SCHEMBL7936712 | 0.80 | MAPT (0.37) | LMNACYP3A4MAPTCYP2C9CYP2C19 | |
| SCHEMBL3057229 | 0.80 | SLC18A2 (0.30) | — | |
| SCHEMBL475361 | 0.78 | APLNR (0.38) | L3MBTL1GAACYP1A2KMT2AMEN1 | |
| SCHEMBL9754770 | 0.78 | GAA (0.31) | L3MBTL1GAA | |
| SCHEMBL3169577 | 0.78 | — | — | |
| SCHEMBL932260 | 0.77 | ADAM17 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1178026-B1 | PROCESSES FOR PRODUCING OXIDE WITH HIGHER OXIDATION THAN ALCOHOL | OTSUKA KAGAKU KK (JP) | 2011-03-30 | — | — | EP | claimed |
| EP-4397755-A2 | DELIVERY OF THERAPEUTIC AGENTS BY A COLLAGEN BINDING PROTEIN | The Board of Trustees of the University of Arkansas (US) | 2024-07-10 | — | — | EP | disclosed |
| EP-3808365-B1 | DELIVERY OF THERAPEUTIC AGENTS BY A COLLAGEN BINDING PROTEIN | UNIV ARKANSAS (US) | 2024-01-31 | — | — | EP | disclosed |
| WO-2022210565-A1 | DNP-MRI SYSTEM, DEVICE, AND CONTROL METHOD, AND INFORMATION DERIVATION METHOD AND DIAGNOSTIC METHOD EMPLOYING DNP-MRI SYSTEM | 国立大学法人東海国立大学機構 | 2022-10-06 | — | — | WO | disclosed |
| US-11279922-B2 | Delivery of therapeutic agents by a collagen binding protein | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2022-03-22 | — | — | US | disclosed |
| EP-3671217-A1 | INVENTION RELATING TO DIAGNOSIS OF TRANSPLANT REJECTION | Justus-Liebig-Universität Gießen (DE) | 2020-06-24 | — | — | EP | disclosed |
| EP-1178026-B1 | PROCESSES FOR PRODUCING OXIDE WITH HIGHER OXIDATION THAN ALCOHOL | OTSUKA KAGAKU KK (JP) | 2011-03-30 | — | — | EP | disclosed |
| US-7183421-B2 | Processes for producing oxide with higher oxidation than alcohol | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 2007-02-27 | — | — | US | disclosed |
| US-20050014957-A1 | Processes for producing oxide with higher oxidation than alcohol | TANAKA HIDEO (JP) | 2005-01-20 | — | — | US | disclosed |
| US-6797830-B2 | SILICA GEL CARRIES AN ALCOHOL AND AN OXIDATIVE CATALYST AND OXIDIZING THE ALCOHOL IN THE PRESENCE OF AN OXIDIZER | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 2004-09-28 | — | — | US | disclosed |
| US-20030114712-A1 | Process for producing oxide with higher oxidation than alcohol | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 2003-06-19 | — | — | US | disclosed |
| EP-1186588-A1 | 6-HYDROXY-2-NAPHTHYLCARBINOL AND PROCESS FOR THE PREPARATION THEREOF | MITSUBISHI CHEMICAL CORPORATION (JP) | 2002-03-13 | — | — | EP | disclosed |
| EP-1178026-A1 | PROCESSES FOR PRODUCING OXIDE WITH HIGHER OXIDATION THAN ALCOHOL | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 2002-02-06 | — | — | EP | disclosed |
| US-6239145-B1 | USABLE IN ACQUIRING INFORMATION ABOUT ACTIVE OXYGEN OR IN VIVO FREE RADICALS AS BIOLOGICAL IMAGES SUCH AS MAGNETIC RESONANCE IMAGES OR MAGNETOENCEPHALOGRAMS; | DAIITCHI RADIOISOTOPE LABORATORIES, LTD. (JP) | 2001-05-29 | — | — | US | disclosed |
| EP-0995740-A1 | NOVEL NITROXYL COMPOUNDS AND DRUGS AND REAGENTS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | DAIICHI RADIOISOTOPE LABORATORIES, LTD. (JP) | 2000-04-26 | — | — | EP | disclosed |
| US-4925652-A | NUCLEAR MAGNETIC RESONANCE | SCHERING AKTIENGESELLSCHAFT (DE) | 1990-05-15 | — | — | US | disclosed |
| US-4845090-A | NUCLEAR MAGNETIC RESONANCE | SCHERING AKTIENGESELLSCHAFT (DE) | 1989-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014957-A1 | Processes for producing oxide with higher oxidation than alcohol | ADH1A, NOX4, AOX1 | ATM 1140/4885LMNA 2655/4885L3MBTL1 4784/4885 |
| US-11279922-B2 | Delivery of therapeutic agents by a collagen binding protein | PTH1R, GHRHR, FGF23 | ATM 4050/4885LMNA 1440/4885L3MBTL1 3567/4885 |
| US-20030114712-A1 | Process for producing oxide with higher oxidation than alcohol | ADH1A, NOX4, AOX1 | ATM 1126/4885LMNA 2690/4885L3MBTL1 4802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.